| BCBS Highmark Delaware | Ocrelizumab (Ocrevus) and Ocrelizumab and hyaluronidase-ocsq (Ocrevus Zunovo) | 2026-09-01 |
| BCBS Highmark Delaware | Nipocalimab-aahu (Imaavy) | 2026-09-01 |
| BCBS Highmark Delaware | Rozanolixizumab-noli (Rystiggo) | 2026-09-01 |
| BCBS Highmark Delaware | Site of Care | 2026-09-01 |
| BCBS Highmark West Virginia | Ocrelizumab (Ocrevus) and Ocrelizumab and hyaluronidase-ocsq (Ocrevus Zunovo) | 2026-09-01 |
| BCBS Highmark West Virginia | Interleukin-23 Antagonists | 2026-09-01 |
| BCBS Highmark West Virginia | Rozanolixizumab-noli (Rystiggo) | 2026-09-01 |
| BCBS Highmark West Virginia | Pegloticase (Krystexxa) | 2026-09-01 |
| BCBS Highmark West Virginia | Denosumab (Prolia, Xgeva) and Denosumab Biosimilars | 2026-09-01 |
| UHC Commercial Medical & Drug | Clinical Trials – Commercial and Individual Exchange Medical Policy | 2026-09-01 |